⌘K
Loading ticker…
CryoPort, Inc. Common Stock · Healthcare · Pharmaceutical Products
As of 2026-06-26, CryoPort, Inc. Common Stock (CYRX) has a 3-month relative strength percentile of 96 and a leadership percentile of 97 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 76. The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 4.3%, relative volume 1.73×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
3m RS is 96, Market Stance is mixed at 47, A/D rating A
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Daily range, ATR, beta, and the math for a 1-ADR stop.
CYRX is in a stage 2 uptrend, week 7. Currently in a 16-day base; basing ADR 4.3% (broad 4.8%). VCP detected: inconclusive. RS line at new high since base start. Distance from 50d / 200d: 19.5% / 55.3%.
Strong relative strength, but attention is quiet relative to this name’s own recent norm. Academic work links low public attention to better forward returns on average — context to weigh, not a forecast.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Related searches
CYRX is held by 5 ETFs as of Mar 2026. Top owner: VTI at 0.00% weight, $12M notional. Top 3 carry $27M.
Top 5 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value |
|---|---|---|
| VTIVanguard Total Stock Market ETF | 0.00% | $12M |
| IWMiShares Russell 2000 ETF | 0.01% | $10M |
| VXFVanguard Extended Market ETF | 0.01% | $5M |
| IWOiShares Russell 2000 Growth ETF | 0.01% | $784K |
| ITOTiShares Core S&P Total U.S. Stock Market ETF | 0.00% | $523K |
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | CYRX Jan avg: 5.31% median: -2.01% win: 25% σ: 17.66% n: 4 2022-04-12 → 2026-05-29 | CYRX Feb avg: -5.23% median: -8.29% win: 25% σ: 20.04% n: 4 2022-04-12 → 2026-05-29 | CYRX Mar avg: 4.62% median: 4.66% win: 75% σ: 6.27% n: 4 2022-04-12 → 2026-05-29 | CYRX Apr avg: -5.95% median: -8.53% win: 20% σ: 17.97% n: 5 2022-04-12 → 2026-05-29 | CYRX May avg: 4.89% median: 7.71% win: 60% σ: 33.14% n: 5 2022-04-12 → 2026-05-29 | CYRX Jun avg: 1.69% median: 7.71% win: 50% σ: 26.82% n: 4 2022-04-12 → 2026-05-29 (current) | CYRX Jul avg: 11.27% median: 9.17% win: 50% σ: 18.91% n: 4 2022-04-12 → 2026-05-29 | CYRX Aug avg: -0.65% median: -5.62% win: 50% σ: 15.64% n: 4 2022-04-12 → 2026-05-29 | CYRX Sep avg: -8.54% median: -7.87% win: 25% σ: 13.89% n: 4 2022-04-12 → 2026-05-29 | CYRX Oct avg: -8.93% median: -10.21% win: 25% σ: 18.78% n: 4 2022-04-12 → 2026-05-29 | CYRX Nov avg: 6.53% median: 5.21% win: 75% σ: 30.01% n: 4 2022-04-12 → 2026-05-29 | CYRX Dec avg: 2.00% median: 4.84% win: 50% σ: 10.64% n: 4 2022-04-12 → 2026-05-29 |